DD14 / D&D Pharmatech - LARVOL DELTA

D&D Pharmatech's oral obesity drug 'MET-GGo' results in 29.1% weight loss. [Google translate] (HIT News) - "According to the poster, the pharmacokinetic test conducted on beagle dogs confirmed that MET-GGo has a half-life of approximately 101 hours. The official said, 'showed the longest human half-life (more than 15 days) among the GLP-1 series peptides reported so far. This is similar to the preclinical results of MET-097i, which is currently in clinical development as a once-monthly formulation.' 'In light of this, MET-GGo is also expected to show a long half-life that can last more than two weeks in the human body.'....Furthermore, in a 28-day efficacy evaluation in a preclinical obesity mouse model, MET-GGo demonstrated a 29.1% weight loss effect. This showed a significantly greater additional weight loss effect than Eli Lilly's terzepatide (17.7%) and Viking Therapeutics' VK2735 (18.5%) at the same dose, demonstrating higher in vivo peptide activity compared to existing dual-agent agents."

Preclinical • Obesity